nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Fingolimod—multiple sclerosis	0.067	0.214	CbGbCtD
Trametinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0432	0.138	CbGbCtD
Trametinib—CYP2C8—Dexamethasone—multiple sclerosis	0.0402	0.129	CbGbCtD
Trametinib—CYP3A4—Triamcinolone—multiple sclerosis	0.0327	0.105	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0315	0.101	CbGbCtD
Trametinib—CYP3A4—Betamethasone—multiple sclerosis	0.0281	0.0897	CbGbCtD
Trametinib—CYP3A4—Prednisolone—multiple sclerosis	0.0277	0.0885	CbGbCtD
Trametinib—CYP3A4—Prednisone—multiple sclerosis	0.0261	0.0836	CbGbCtD
Trametinib—CYP3A4—Dexamethasone—multiple sclerosis	0.0163	0.0522	CbGbCtD
Trametinib—MAP2K1—brainstem—multiple sclerosis	0.00337	0.137	CbGeAlD
Trametinib—MAP2K1—spinal cord—multiple sclerosis	0.00209	0.0853	CbGeAlD
Trametinib—MAP2K2—medulla oblongata—multiple sclerosis	0.00207	0.0842	CbGeAlD
Trametinib—MAP2K2—midbrain—multiple sclerosis	0.00189	0.077	CbGeAlD
Trametinib—MAP2K2—spinal cord—multiple sclerosis	0.00184	0.0751	CbGeAlD
Trametinib—MAP2K1—nervous system—multiple sclerosis	0.00176	0.0719	CbGeAlD
Trametinib—MAP2K1—central nervous system—multiple sclerosis	0.0017	0.0692	CbGeAlD
Trametinib—MAP2K1—cerebellum—multiple sclerosis	0.00166	0.0676	CbGeAlD
Trametinib—MAP2K2—nervous system—multiple sclerosis	0.00155	0.0633	CbGeAlD
Trametinib—MAP2K2—central nervous system—multiple sclerosis	0.00149	0.0609	CbGeAlD
Trametinib—MAP2K2—cerebellum—multiple sclerosis	0.00146	0.0595	CbGeAlD
Trametinib—MAP2K1—brain—multiple sclerosis	0.00135	0.0549	CbGeAlD
Trametinib—MAP2K2—brain—multiple sclerosis	0.00119	0.0484	CbGeAlD
Trametinib—CYP2C8—brain—multiple sclerosis	0.000411	0.0167	CbGeAlD
Trametinib—CYP3A4—nervous system—multiple sclerosis	0.000364	0.0148	CbGeAlD
Trametinib—Oedema—Mitoxantrone—multiple sclerosis	0.000363	0.00118	CcSEcCtD
Trametinib—Infection—Mitoxantrone—multiple sclerosis	0.000361	0.00118	CcSEcCtD
Trametinib—Eye disorder—Methylprednisolone—multiple sclerosis	0.000359	0.00117	CcSEcCtD
Trametinib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000357	0.00116	CcSEcCtD
Trametinib—Bradycardia—Betamethasone—multiple sclerosis	0.000356	0.00116	CcSEcCtD
Trametinib—Bradycardia—Dexamethasone—multiple sclerosis	0.000356	0.00116	CcSEcCtD
Trametinib—Neutropenia—Prednisone—multiple sclerosis	0.000356	0.00116	CcSEcCtD
Trametinib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000355	0.00116	CcSEcCtD
Trametinib—Abdominal pain—Azathioprine—multiple sclerosis	0.000355	0.00116	CcSEcCtD
Trametinib—Body temperature increased—Azathioprine—multiple sclerosis	0.000355	0.00116	CcSEcCtD
Trametinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000352	0.00115	CcSEcCtD
Trametinib—Haemoglobin—Dexamethasone—multiple sclerosis	0.000351	0.00115	CcSEcCtD
Trametinib—Haemoglobin—Betamethasone—multiple sclerosis	0.000351	0.00115	CcSEcCtD
Trametinib—Vomiting—Cladribine—multiple sclerosis	0.000351	0.00114	CcSEcCtD
Trametinib—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000351	0.00114	CcSEcCtD
Trametinib—CYP3A4—central nervous system—multiple sclerosis	0.000351	0.0143	CbGeAlD
Trametinib—Haemorrhage—Betamethasone—multiple sclerosis	0.00035	0.00114	CcSEcCtD
Trametinib—Haemorrhage—Dexamethasone—multiple sclerosis	0.00035	0.00114	CcSEcCtD
Trametinib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000349	0.00114	CcSEcCtD
Trametinib—Rash—Cladribine—multiple sclerosis	0.000348	0.00113	CcSEcCtD
Trametinib—Dermatitis—Cladribine—multiple sclerosis	0.000348	0.00113	CcSEcCtD
Trametinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000347	0.00113	CcSEcCtD
Trametinib—Headache—Cladribine—multiple sclerosis	0.000346	0.00113	CcSEcCtD
Trametinib—Arrhythmia—Triamcinolone—multiple sclerosis	0.000344	0.00112	CcSEcCtD
Trametinib—Vision blurred—Prednisolone—multiple sclerosis	0.000344	0.00112	CcSEcCtD
Trametinib—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000343	0.00112	CcSEcCtD
Trametinib—Hyperglycaemia—Prednisone—multiple sclerosis	0.000343	0.00112	CcSEcCtD
Trametinib—Mental disorder—Methylprednisolone—multiple sclerosis	0.000337	0.0011	CcSEcCtD
Trametinib—Erythema—Triamcinolone—multiple sclerosis	0.000335	0.00109	CcSEcCtD
Trametinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000335	0.00109	CcSEcCtD
Trametinib—Erythema—Methylprednisolone—multiple sclerosis	0.000335	0.00109	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000331	0.00108	CcSEcCtD
Trametinib—Dysgeusia—Triamcinolone—multiple sclerosis	0.000329	0.00107	CcSEcCtD
Trametinib—Nausea—Cladribine—multiple sclerosis	0.000328	0.00107	CcSEcCtD
Trametinib—Eye disorder—Betamethasone—multiple sclerosis	0.000327	0.00107	CcSEcCtD
Trametinib—Eye disorder—Dexamethasone—multiple sclerosis	0.000327	0.00107	CcSEcCtD
Trametinib—Back pain—Triamcinolone—multiple sclerosis	0.000324	0.00106	CcSEcCtD
Trametinib—Angiopathy—Dexamethasone—multiple sclerosis	0.000317	0.00103	CcSEcCtD
Trametinib—Angiopathy—Betamethasone—multiple sclerosis	0.000317	0.00103	CcSEcCtD
Trametinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000315	0.00103	CcSEcCtD
Trametinib—Hypertension—Prednisolone—multiple sclerosis	0.000315	0.00103	CcSEcCtD
Trametinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000313	0.00102	CcSEcCtD
Trametinib—Arrhythmia—Betamethasone—multiple sclerosis	0.000312	0.00102	CcSEcCtD
Trametinib—Arrhythmia—Dexamethasone—multiple sclerosis	0.000312	0.00102	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—multiple sclerosis	0.000312	0.00102	CcSEcCtD
Trametinib—Constipation—Mitoxantrone—multiple sclerosis	0.00031	0.00101	CcSEcCtD
Trametinib—Bradycardia—Prednisone—multiple sclerosis	0.00031	0.00101	CcSEcCtD
Trametinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000307	0.001	CcSEcCtD
Trametinib—Haemoglobin—Prednisone—multiple sclerosis	0.000306	0.000998	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000305	0.000994	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—multiple sclerosis	0.000305	0.000993	CcSEcCtD
Trametinib—Erythema—Dexamethasone—multiple sclerosis	0.000304	0.000992	CcSEcCtD
Trametinib—Erythema—Betamethasone—multiple sclerosis	0.000304	0.000992	CcSEcCtD
Trametinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000299	0.000975	CcSEcCtD
Trametinib—Oedema—Prednisolone—multiple sclerosis	0.000298	0.00097	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—multiple sclerosis	0.000297	0.000969	CcSEcCtD
Trametinib—Dizziness—Azathioprine—multiple sclerosis	0.000297	0.000968	CcSEcCtD
Trametinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000297	0.000967	CcSEcCtD
Trametinib—Cough—Triamcinolone—multiple sclerosis	0.000293	0.000954	CcSEcCtD
Trametinib—Hypertension—Triamcinolone—multiple sclerosis	0.00029	0.000944	CcSEcCtD
Trametinib—Hypertension—Methylprednisolone—multiple sclerosis	0.000289	0.000942	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000288	0.000938	CcSEcCtD
Trametinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000287	0.000935	CcSEcCtD
Trametinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000287	0.000935	CcSEcCtD
Trametinib—Myalgia—Triamcinolone—multiple sclerosis	0.000286	0.000931	CcSEcCtD
Trametinib—Vomiting—Azathioprine—multiple sclerosis	0.000285	0.00093	CcSEcCtD
Trametinib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000285	0.000929	CcSEcCtD
Trametinib—Myalgia—Methylprednisolone—multiple sclerosis	0.000285	0.000929	CcSEcCtD
Trametinib—Eye disorder—Prednisone—multiple sclerosis	0.000285	0.000928	CcSEcCtD
Trametinib—Infestation—Methotrexate—multiple sclerosis	0.000283	0.000924	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000283	0.000924	CcSEcCtD
Trametinib—Rash—Azathioprine—multiple sclerosis	0.000283	0.000923	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000283	0.000923	CcSEcCtD
Trametinib—Dermatitis—Azathioprine—multiple sclerosis	0.000283	0.000922	CcSEcCtD
Trametinib—Headache—Azathioprine—multiple sclerosis	0.000281	0.000917	CcSEcCtD
Trametinib—Dry mouth—Triamcinolone—multiple sclerosis	0.000279	0.00091	CcSEcCtD
Trametinib—Renal failure—Methotrexate—multiple sclerosis	0.000279	0.000908	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—multiple sclerosis	0.000276	0.000901	CcSEcCtD
Trametinib—Angiopathy—Prednisone—multiple sclerosis	0.000276	0.000901	CcSEcCtD
Trametinib—Oedema—Triamcinolone—multiple sclerosis	0.000274	0.000892	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—multiple sclerosis	0.000272	0.000887	CcSEcCtD
Trametinib—Infection—Triamcinolone—multiple sclerosis	0.000272	0.000887	CcSEcCtD
Trametinib—Infection—Methylprednisolone—multiple sclerosis	0.000271	0.000885	CcSEcCtD
Trametinib—Haematuria—Methotrexate—multiple sclerosis	0.00027	0.000881	CcSEcCtD
Trametinib—Insomnia—Prednisolone—multiple sclerosis	0.000269	0.000878	CcSEcCtD
Trametinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000268	0.000873	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—multiple sclerosis	0.000267	0.000872	CcSEcCtD
Trametinib—Mental disorder—Prednisone—multiple sclerosis	0.000267	0.00087	CcSEcCtD
Trametinib—Nausea—Azathioprine—multiple sclerosis	0.000267	0.000869	CcSEcCtD
Trametinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000265	0.000865	CcSEcCtD
Trametinib—Erythema—Prednisone—multiple sclerosis	0.000265	0.000864	CcSEcCtD
Trametinib—Malnutrition—Prednisone—multiple sclerosis	0.000265	0.000864	CcSEcCtD
Trametinib—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000265	0.000863	CcSEcCtD
Trametinib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000264	0.000861	CcSEcCtD
Trametinib—Hypertension—Betamethasone—multiple sclerosis	0.000263	0.000857	CcSEcCtD
Trametinib—Hypertension—Dexamethasone—multiple sclerosis	0.000263	0.000857	CcSEcCtD
Trametinib—Asthenia—Mitoxantrone—multiple sclerosis	0.00026	0.000849	CcSEcCtD
Trametinib—Myalgia—Dexamethasone—multiple sclerosis	0.000259	0.000845	CcSEcCtD
Trametinib—Myalgia—Betamethasone—multiple sclerosis	0.000259	0.000845	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—multiple sclerosis	0.000256	0.000834	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—multiple sclerosis	0.000254	0.00083	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000251	0.000819	CcSEcCtD
Trametinib—Vision blurred—Prednisone—multiple sclerosis	0.00025	0.000814	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—multiple sclerosis	0.000249	0.000813	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000249	0.000813	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000249	0.000811	CcSEcCtD
Trametinib—Oedema—Dexamethasone—multiple sclerosis	0.000248	0.00081	CcSEcCtD
Trametinib—Oedema—Betamethasone—multiple sclerosis	0.000248	0.00081	CcSEcCtD
Trametinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000248	0.000809	CcSEcCtD
Trametinib—Insomnia—Triamcinolone—multiple sclerosis	0.000248	0.000807	CcSEcCtD
Trametinib—Insomnia—Methylprednisolone—multiple sclerosis	0.000247	0.000805	CcSEcCtD
Trametinib—Infection—Betamethasone—multiple sclerosis	0.000247	0.000804	CcSEcCtD
Trametinib—Infection—Dexamethasone—multiple sclerosis	0.000247	0.000804	CcSEcCtD
Trametinib—Anaemia—Prednisone—multiple sclerosis	0.000245	0.000799	CcSEcCtD
Trametinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000244	0.000794	CcSEcCtD
Trametinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000244	0.000794	CcSEcCtD
Trametinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000243	0.000793	CcSEcCtD
Trametinib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000243	0.000793	CcSEcCtD
Trametinib—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00024	0.000783	CcSEcCtD
Trametinib—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00024	0.000783	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—multiple sclerosis	0.000238	0.000775	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000236	0.00077	CcSEcCtD
Trametinib—Fatigue—Triamcinolone—multiple sclerosis	0.000236	0.000769	CcSEcCtD
Trametinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000236	0.000768	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—multiple sclerosis	0.000231	0.000753	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000231	0.000752	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000229	0.000748	CcSEcCtD
Trametinib—Hypertension—Prednisone—multiple sclerosis	0.000229	0.000746	CcSEcCtD
Trametinib—Rash—Mitoxantrone—multiple sclerosis	0.000229	0.000746	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000229	0.000745	CcSEcCtD
Trametinib—Chills—Methotrexate—multiple sclerosis	0.000228	0.000744	CcSEcCtD
Trametinib—Headache—Mitoxantrone—multiple sclerosis	0.000227	0.000741	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000226	0.000738	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000226	0.000738	CcSEcCtD
Trametinib—Arthralgia—Prednisone—multiple sclerosis	0.000226	0.000736	CcSEcCtD
Trametinib—Myalgia—Prednisone—multiple sclerosis	0.000226	0.000736	CcSEcCtD
Trametinib—Insomnia—Dexamethasone—multiple sclerosis	0.000225	0.000732	CcSEcCtD
Trametinib—Insomnia—Betamethasone—multiple sclerosis	0.000225	0.000732	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000224	0.000731	CcSEcCtD
Trametinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000223	0.000728	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—multiple sclerosis	0.000223	0.000727	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—multiple sclerosis	0.000222	0.000722	CcSEcCtD
Trametinib—Erythema—Methotrexate—multiple sclerosis	0.000222	0.000722	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—multiple sclerosis	0.000217	0.000707	CcSEcCtD
Trametinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000216	0.000706	CcSEcCtD
Trametinib—Oedema—Prednisone—multiple sclerosis	0.000216	0.000705	CcSEcCtD
Trametinib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000216	0.000704	CcSEcCtD
Trametinib—Decreased appetite—Betamethasone—multiple sclerosis	0.000216	0.000704	CcSEcCtD
Trametinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000216	0.000704	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—multiple sclerosis	0.000216	0.000703	CcSEcCtD
Trametinib—Infection—Prednisone—multiple sclerosis	0.000215	0.000701	CcSEcCtD
Trametinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000214	0.000699	CcSEcCtD
Trametinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000214	0.000699	CcSEcCtD
Trametinib—Back pain—Methotrexate—multiple sclerosis	0.000214	0.000699	CcSEcCtD
Trametinib—Fatigue—Dexamethasone—multiple sclerosis	0.000214	0.000698	CcSEcCtD
Trametinib—Fatigue—Betamethasone—multiple sclerosis	0.000214	0.000698	CcSEcCtD
Trametinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000212	0.000692	CcSEcCtD
Trametinib—Skin disorder—Prednisone—multiple sclerosis	0.00021	0.000685	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—multiple sclerosis	0.000209	0.000682	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—multiple sclerosis	0.000209	0.000681	CcSEcCtD
Trametinib—Anaemia—Methotrexate—multiple sclerosis	0.000205	0.000667	CcSEcCtD
Trametinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000203	0.000662	CcSEcCtD
Trametinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000203	0.000662	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—multiple sclerosis	0.000198	0.000646	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000197	0.000643	CcSEcCtD
Trametinib—Dizziness—Prednisolone—multiple sclerosis	0.000197	0.000642	CcSEcCtD
Trametinib—Asthenia—Triamcinolone—multiple sclerosis	0.000196	0.00064	CcSEcCtD
Trametinib—Abdominal pain—Betamethasone—multiple sclerosis	0.000196	0.00064	CcSEcCtD
Trametinib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000196	0.00064	CcSEcCtD
Trametinib—Body temperature increased—Betamethasone—multiple sclerosis	0.000196	0.00064	CcSEcCtD
Trametinib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000196	0.00064	CcSEcCtD
Trametinib—Asthenia—Methylprednisolone—multiple sclerosis	0.000196	0.000639	CcSEcCtD
Trametinib—Insomnia—Prednisone—multiple sclerosis	0.000196	0.000638	CcSEcCtD
Trametinib—Pruritus—Triamcinolone—multiple sclerosis	0.000194	0.000631	CcSEcCtD
Trametinib—Cough—Methotrexate—multiple sclerosis	0.000193	0.00063	CcSEcCtD
Trametinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000193	0.00063	CcSEcCtD
Trametinib—Myalgia—Methotrexate—multiple sclerosis	0.000189	0.000615	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—multiple sclerosis	0.000189	0.000615	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—multiple sclerosis	0.000188	0.000613	CcSEcCtD
Trametinib—Rash—Prednisolone—multiple sclerosis	0.000188	0.000612	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—multiple sclerosis	0.000188	0.000611	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000187	0.000611	CcSEcCtD
Trametinib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000187	0.000609	CcSEcCtD
Trametinib—Fatigue—Prednisone—multiple sclerosis	0.000187	0.000608	CcSEcCtD
Trametinib—Headache—Prednisolone—multiple sclerosis	0.000187	0.000608	CcSEcCtD
Trametinib—Constipation—Prednisone—multiple sclerosis	0.000185	0.000603	CcSEcCtD
Trametinib—Dizziness—Triamcinolone—multiple sclerosis	0.000181	0.00059	CcSEcCtD
Trametinib—Dizziness—Methylprednisolone—multiple sclerosis	0.000181	0.000589	CcSEcCtD
Trametinib—Infection—Methotrexate—multiple sclerosis	0.00018	0.000586	CcSEcCtD
Trametinib—Asthenia—Betamethasone—multiple sclerosis	0.000178	0.000581	CcSEcCtD
Trametinib—Asthenia—Dexamethasone—multiple sclerosis	0.000178	0.000581	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000177	0.000578	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000177	0.000577	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000177	0.000577	CcSEcCtD
Trametinib—Nausea—Prednisolone—multiple sclerosis	0.000177	0.000576	CcSEcCtD
Trametinib—Pruritus—Betamethasone—multiple sclerosis	0.000176	0.000573	CcSEcCtD
Trametinib—Pruritus—Dexamethasone—multiple sclerosis	0.000176	0.000573	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—multiple sclerosis	0.000176	0.000572	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000175	0.00057	CcSEcCtD
Trametinib—Vomiting—Triamcinolone—multiple sclerosis	0.000174	0.000567	CcSEcCtD
Trametinib—Vomiting—Methylprednisolone—multiple sclerosis	0.000174	0.000566	CcSEcCtD
Trametinib—Rash—Triamcinolone—multiple sclerosis	0.000173	0.000563	CcSEcCtD
Trametinib—Dermatitis—Triamcinolone—multiple sclerosis	0.000172	0.000562	CcSEcCtD
Trametinib—Rash—Methylprednisolone—multiple sclerosis	0.000172	0.000561	CcSEcCtD
Trametinib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000172	0.000561	CcSEcCtD
Trametinib—Headache—Triamcinolone—multiple sclerosis	0.000172	0.000559	CcSEcCtD
Trametinib—Headache—Methylprednisolone—multiple sclerosis	0.000171	0.000558	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—multiple sclerosis	0.000171	0.000557	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—multiple sclerosis	0.000171	0.000557	CcSEcCtD
Trametinib—Diarrhoea—Dexamethasone—multiple sclerosis	0.00017	0.000554	CcSEcCtD
Trametinib—Diarrhoea—Betamethasone—multiple sclerosis	0.00017	0.000554	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000165	0.000537	CcSEcCtD
Trametinib—Dizziness—Betamethasone—multiple sclerosis	0.000164	0.000535	CcSEcCtD
Trametinib—Dizziness—Dexamethasone—multiple sclerosis	0.000164	0.000535	CcSEcCtD
Trametinib—Insomnia—Methotrexate—multiple sclerosis	0.000164	0.000533	CcSEcCtD
Trametinib—Nausea—Triamcinolone—multiple sclerosis	0.000163	0.00053	CcSEcCtD
Trametinib—Nausea—Methylprednisolone—multiple sclerosis	0.000162	0.000529	CcSEcCtD
Trametinib—Vomiting—Dexamethasone—multiple sclerosis	0.000158	0.000515	CcSEcCtD
Trametinib—Vomiting—Betamethasone—multiple sclerosis	0.000158	0.000515	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—multiple sclerosis	0.000157	0.000512	CcSEcCtD
Trametinib—Rash—Betamethasone—multiple sclerosis	0.000157	0.000511	CcSEcCtD
Trametinib—Rash—Dexamethasone—multiple sclerosis	0.000157	0.000511	CcSEcCtD
Trametinib—Dermatitis—Betamethasone—multiple sclerosis	0.000156	0.00051	CcSEcCtD
Trametinib—Dermatitis—Dexamethasone—multiple sclerosis	0.000156	0.00051	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000156	0.000509	CcSEcCtD
Trametinib—Fatigue—Methotrexate—multiple sclerosis	0.000156	0.000508	CcSEcCtD
Trametinib—Headache—Betamethasone—multiple sclerosis	0.000156	0.000507	CcSEcCtD
Trametinib—Headache—Dexamethasone—multiple sclerosis	0.000156	0.000507	CcSEcCtD
Trametinib—Asthenia—Prednisone—multiple sclerosis	0.000155	0.000506	CcSEcCtD
Trametinib—Pruritus—Prednisone—multiple sclerosis	0.000153	0.000499	CcSEcCtD
Trametinib—Diarrhoea—Prednisone—multiple sclerosis	0.000148	0.000483	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000148	0.000482	CcSEcCtD
Trametinib—Nausea—Betamethasone—multiple sclerosis	0.000148	0.000481	CcSEcCtD
Trametinib—Nausea—Dexamethasone—multiple sclerosis	0.000148	0.000481	CcSEcCtD
Trametinib—Dizziness—Prednisone—multiple sclerosis	0.000143	0.000466	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—multiple sclerosis	0.000143	0.000466	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—multiple sclerosis	0.000143	0.000466	CcSEcCtD
Trametinib—Vomiting—Prednisone—multiple sclerosis	0.000138	0.000448	CcSEcCtD
Trametinib—Rash—Prednisone—multiple sclerosis	0.000136	0.000445	CcSEcCtD
Trametinib—Dermatitis—Prednisone—multiple sclerosis	0.000136	0.000444	CcSEcCtD
Trametinib—Headache—Prednisone—multiple sclerosis	0.000136	0.000442	CcSEcCtD
Trametinib—Asthenia—Methotrexate—multiple sclerosis	0.00013	0.000423	CcSEcCtD
Trametinib—Nausea—Prednisone—multiple sclerosis	0.000129	0.000419	CcSEcCtD
Trametinib—Pruritus—Methotrexate—multiple sclerosis	0.000128	0.000417	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—multiple sclerosis	0.000124	0.000403	CcSEcCtD
Trametinib—Dizziness—Methotrexate—multiple sclerosis	0.00012	0.00039	CcSEcCtD
Trametinib—Vomiting—Methotrexate—multiple sclerosis	0.000115	0.000375	CcSEcCtD
Trametinib—Rash—Methotrexate—multiple sclerosis	0.000114	0.000372	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—multiple sclerosis	0.000114	0.000371	CcSEcCtD
Trametinib—Headache—Methotrexate—multiple sclerosis	0.000113	0.000369	CcSEcCtD
Trametinib—Nausea—Methotrexate—multiple sclerosis	0.000107	0.00035	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—GPR65—multiple sclerosis	6.58e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCR2—multiple sclerosis	6.56e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—multiple sclerosis	6.55e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD28—multiple sclerosis	6.53e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CNR1—multiple sclerosis	6.47e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	6.46e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCR1—multiple sclerosis	6.43e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL13—multiple sclerosis	6.43e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTPRC—multiple sclerosis	6.41e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CCR2—multiple sclerosis	6.41e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TLR4—multiple sclerosis	6.32e-05	0.000178	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—multiple sclerosis	6.26e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—multiple sclerosis	6.23e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—multiple sclerosis	6.2e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	6.2e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—multiple sclerosis	6.2e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DPB1—multiple sclerosis	6.2e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—multiple sclerosis	6.19e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—multiple sclerosis	6.16e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MMP9—multiple sclerosis	6.15e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	6.15e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—multiple sclerosis	6.14e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD28—multiple sclerosis	6.11e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—multiple sclerosis	6.09e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—multiple sclerosis	6.06e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CNR1—multiple sclerosis	6.06e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—STAT3—multiple sclerosis	6.05e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD28—multiple sclerosis	6.03e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCR1—multiple sclerosis	6.02e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL13—multiple sclerosis	6.02e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTPRC—multiple sclerosis	6e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CCR2—multiple sclerosis	6e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ITGA4—multiple sclerosis	5.96e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40—multiple sclerosis	5.96e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNB1—multiple sclerosis	5.92e-05	0.000166	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TLR4—multiple sclerosis	5.91e-05	0.000166	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTLA4—multiple sclerosis	5.87e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD80—multiple sclerosis	5.83e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL10—multiple sclerosis	5.83e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—multiple sclerosis	5.8e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—multiple sclerosis	5.8e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	5.8e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DPB1—multiple sclerosis	5.8e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—multiple sclerosis	5.76e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	5.75e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—multiple sclerosis	5.75e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—multiple sclerosis	5.7e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—multiple sclerosis	5.67e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—STAT3—multiple sclerosis	5.66e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD28—multiple sclerosis	5.64e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	5.59e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TYK2—multiple sclerosis	5.58e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40—multiple sclerosis	5.58e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ITGA4—multiple sclerosis	5.58e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNB1—multiple sclerosis	5.53e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MAPK1—multiple sclerosis	5.5e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTLA4—multiple sclerosis	5.49e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	5.49e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD80—multiple sclerosis	5.46e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL10—multiple sclerosis	5.45e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	5.31e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	5.23e-05	0.000147	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	5.22e-05	0.000147	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	5.22e-05	0.000147	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TYK2—multiple sclerosis	5.22e-05	0.000147	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—VCAM1—multiple sclerosis	5.18e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DQA1—multiple sclerosis	5.17e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MAPK1—multiple sclerosis	5.14e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	5.14e-05	0.000144	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.11e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL5—multiple sclerosis	5.02e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MAPK1—multiple sclerosis	4.97e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	4.96e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TYK2—multiple sclerosis	4.92e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—VCAM1—multiple sclerosis	4.85e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DQA1—multiple sclerosis	4.84e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DQB1—multiple sclerosis	4.84e-05	0.000136	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPC5—multiple sclerosis	4.78e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL5—multiple sclerosis	4.69e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD86—multiple sclerosis	4.66e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MAPK1—multiple sclerosis	4.65e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TYK2—multiple sclerosis	4.61e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL3—multiple sclerosis	4.58e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40LG—multiple sclerosis	4.57e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DQB1—multiple sclerosis	4.53e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCR5—multiple sclerosis	4.52e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—multiple sclerosis	4.52e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2RA—multiple sclerosis	4.46e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD4—multiple sclerosis	4.45e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTGER4—multiple sclerosis	4.41e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—multiple sclerosis	4.39e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD86—multiple sclerosis	4.36e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-B—multiple sclerosis	4.34e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PGR—multiple sclerosis	4.34e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD86—multiple sclerosis	4.3e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—multiple sclerosis	4.3e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL3—multiple sclerosis	4.29e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40LG—multiple sclerosis	4.27e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCR3—multiple sclerosis	4.26e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCR5—multiple sclerosis	4.23e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—multiple sclerosis	4.23e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—multiple sclerosis	4.22e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD28—multiple sclerosis	4.22e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2RA—multiple sclerosis	4.17e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD4—multiple sclerosis	4.17e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCR2—multiple sclerosis	4.14e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTGER4—multiple sclerosis	4.13e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—multiple sclerosis	4.11e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2RA—multiple sclerosis	4.07e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-B—multiple sclerosis	4.06e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PGR—multiple sclerosis	4.06e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-A—multiple sclerosis	4.03e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD86—multiple sclerosis	4.02e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—multiple sclerosis	4.02e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCR3—multiple sclerosis	3.99e-05	0.000112	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SRM—multiple sclerosis	3.98e-05	0.000112	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RRM1—multiple sclerosis	3.96e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—multiple sclerosis	3.95e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD28—multiple sclerosis	3.95e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—STAT3—multiple sclerosis	3.9e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCR2—multiple sclerosis	3.88e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CNR1—multiple sclerosis	3.82e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—multiple sclerosis	3.82e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CCR5—multiple sclerosis	3.81e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2RA—multiple sclerosis	3.81e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-A—multiple sclerosis	3.77e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HLA-A—multiple sclerosis	3.72e-05	0.000104	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.69e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TLR4—multiple sclerosis	3.68e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DRB1—multiple sclerosis	3.68e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—multiple sclerosis	3.65e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—multiple sclerosis	3.62e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CNR1—multiple sclerosis	3.58e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—multiple sclerosis	3.58e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CCR5—multiple sclerosis	3.57e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK1—multiple sclerosis	3.55e-05	9.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—POMC—multiple sclerosis	3.53e-05	9.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ICAM1—multiple sclerosis	3.53e-05	9.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HLA-A—multiple sclerosis	3.48e-05	9.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOE—multiple sclerosis	3.47e-05	9.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL2—multiple sclerosis	3.46e-05	9.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—multiple sclerosis	3.44e-05	9.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL10—multiple sclerosis	3.44e-05	9.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DRB1—multiple sclerosis	3.44e-05	9.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD80—multiple sclerosis	3.4e-05	9.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—multiple sclerosis	3.39e-05	9.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—multiple sclerosis	3.38e-05	9.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK1—multiple sclerosis	3.32e-05	9.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—POMC—multiple sclerosis	3.31e-05	9.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ICAM1—multiple sclerosis	3.3e-05	9.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOE—multiple sclerosis	3.25e-05	9.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL2—multiple sclerosis	3.23e-05	9.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL10—multiple sclerosis	3.22e-05	9.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD80—multiple sclerosis	3.18e-05	8.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—multiple sclerosis	3.16e-05	8.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—TYK2—multiple sclerosis	3.14e-05	8.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD80—multiple sclerosis	3.14e-05	8.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK1—multiple sclerosis	3.13e-05	8.81e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.07e-05	8.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD86—multiple sclerosis	3.01e-05	8.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL5—multiple sclerosis	2.96e-05	8.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—TYK2—multiple sclerosis	2.94e-05	8.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD80—multiple sclerosis	2.93e-05	8.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK1—multiple sclerosis	2.93e-05	8.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TYK2—multiple sclerosis	2.87e-05	8.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD86—multiple sclerosis	2.82e-05	7.92e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.8e-05	7.88e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.8e-05	7.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL5—multiple sclerosis	2.77e-05	7.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SPP1—multiple sclerosis	2.75e-05	7.71e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—multiple sclerosis	2.73e-05	7.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNG—multiple sclerosis	2.69e-05	7.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TYK2—multiple sclerosis	2.68e-05	7.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCR5—multiple sclerosis	2.67e-05	7.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TYK2—multiple sclerosis	2.65e-05	7.44e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.64e-05	7.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2RA—multiple sclerosis	2.63e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—multiple sclerosis	2.61e-05	7.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—multiple sclerosis	2.59e-05	7.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SPP1—multiple sclerosis	2.57e-05	7.22e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.56e-05	7.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—multiple sclerosis	2.55e-05	7.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—multiple sclerosis	2.51e-05	7.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCR5—multiple sclerosis	2.5e-05	7.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TYK2—multiple sclerosis	2.48e-05	6.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2RA—multiple sclerosis	2.46e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—multiple sclerosis	2.44e-05	6.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOE—multiple sclerosis	2.43e-05	6.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—multiple sclerosis	2.43e-05	6.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—multiple sclerosis	2.41e-05	6.77e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.41e-05	6.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—multiple sclerosis	2.4e-05	6.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—multiple sclerosis	2.39e-05	6.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—multiple sclerosis	2.39e-05	6.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BCHE—multiple sclerosis	2.27e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOE—multiple sclerosis	2.27e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—multiple sclerosis	2.25e-05	6.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—multiple sclerosis	2.24e-05	6.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—multiple sclerosis	2.24e-05	6.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—multiple sclerosis	2.23e-05	6.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD80—multiple sclerosis	2.2e-05	6.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.13e-05	5.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—POMC—multiple sclerosis	2.09e-05	5.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD80—multiple sclerosis	2.06e-05	5.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL2—multiple sclerosis	2.04e-05	5.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—multiple sclerosis	2.01e-05	5.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK1—multiple sclerosis	2e-05	5.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—POMC—multiple sclerosis	1.95e-05	5.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL2—multiple sclerosis	1.91e-05	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—multiple sclerosis	1.88e-05	5.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK1—multiple sclerosis	1.87e-05	5.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TYK2—multiple sclerosis	1.85e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—multiple sclerosis	1.85e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK1—multiple sclerosis	1.83e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TYK2—multiple sclerosis	1.73e-05	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—multiple sclerosis	1.73e-05	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—multiple sclerosis	1.72e-05	4.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—multiple sclerosis	1.72e-05	4.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK1—multiple sclerosis	1.71e-05	4.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK1—multiple sclerosis	1.69e-05	4.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—multiple sclerosis	1.61e-05	4.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—multiple sclerosis	1.61e-05	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK1—multiple sclerosis	1.58e-05	4.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—multiple sclerosis	1.54e-05	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—multiple sclerosis	1.54e-05	4.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—multiple sclerosis	1.46e-05	4.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—multiple sclerosis	1.44e-05	4.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—multiple sclerosis	1.44e-05	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—multiple sclerosis	1.4e-05	3.94e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOE—multiple sclerosis	1.37e-05	3.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—multiple sclerosis	1.37e-05	3.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—multiple sclerosis	1.31e-05	3.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—multiple sclerosis	1.3e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—multiple sclerosis	1.3e-05	3.64e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.22e-05	3.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—multiple sclerosis	1.21e-05	3.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—multiple sclerosis	1.21e-05	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—multiple sclerosis	1.21e-05	3.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—multiple sclerosis	1.2e-05	3.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK1—multiple sclerosis	1.18e-05	3.32e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POMC—multiple sclerosis	1.18e-05	3.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—multiple sclerosis	1.13e-05	3.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—multiple sclerosis	1.13e-05	3.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK1—multiple sclerosis	1.1e-05	3.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—multiple sclerosis	1.07e-05	3.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—multiple sclerosis	9.07e-06	2.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—multiple sclerosis	8.49e-06	2.38e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOE—multiple sclerosis	7.34e-06	2.06e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POMC—multiple sclerosis	6.31e-06	1.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—multiple sclerosis	5.75e-06	1.62e-05	CbGpPWpGaD
